Skip header and navigation

Refine By

   MORE

22 records – page 1 of 3.

Alternating mitomycin C and BCG instillations versus BCG alone in treatment of carcinoma in situ of the urinary bladder: a nordic study.

https://arctichealth.org/en/permalink/ahliterature18415
Source
Eur Urol. 2003 Jun;43(6):637-45
Publication Type
Article
Date
Jun-2003
Author
Eero Kaasinen
Hans Wijkström
Per Uno Malmström
Sverker Hellsten
Milos Duchek
Oddvar Mestad
Erkki Rintala
Author Affiliation
Department of Surgery, Hyvinkää Hospital, Sairaalakatu 1, FIN-05850 Hyvinkää, Finland. eero.kaasinen@hus.fi
Source
Eur Urol. 2003 Jun;43(6):637-45
Date
Jun-2003
Language
English
Publication Type
Article
Keywords
Adjuvants, Immunologic - administration & dosage
Administration, Intravesical
Aged
Antibiotics, Antineoplastic - administration & dosage - therapeutic use
BCG Vaccine - administration & dosage
Bladder Neoplasms - drug therapy - therapy
Carcinoma in Situ - drug therapy - therapy
Combined Modality Therapy
Disease-Free Survival
Female
Humans
Male
Mitomycin - administration & dosage - therapeutic use
Neoplasm Recurrence, Local - prevention & control
Research Support, Non-U.S. Gov't
Scandinavia
Abstract
OBJECTIVES: To evaluate whether, in patients with carcinoma in situ (CIS) of the urinary bladder, alternating instillation therapy with mitomycin C (MMC) and bacillus Calmette-Guerin (BCG) was more effective and less toxic than conventional BCG monotherapy. METHODS: Patients were stratified prospectively for primary, secondary, and concomitant CIS and randomized to one of two regimens. Patients in the alternating group received six weekly intravesical instillations of MMC 40 mg, followed by alternating monthly instillations of BCG 120 mg and MMC for one year. In the monotherapy group, only BCG was instilled on the same schedule. RESULTS: Of 323 enrolled patients, 304 were eligible for analysis. After an overall median follow-up of 56 months, the Kaplan-Meier disease-free estimate for BCG monotherapy was significantly better than that for alternating therapy (p=0.03; log rank test). Risk for progression appeared lower in the BCG monotherapy group (p=0.07), but no differences existed in survival. Besides the regimen, CIS category also predicted outcome to some extent. BCG monotherapy caused significantly more local side-effects and premature cessation of instillation treatment than did the alternating therapy. However, no differences were observed in the number of serious side-effects. CONCLUSION: One-year BCG monotherapy was more effective than the alternating therapy for reducing recurrence and compared well with the best regimens reported from substantially smaller series. The alternating therapy was better tolerated.
PubMed ID
12767365 View in PubMed
Less detail

Chemoradiotherapy of anal carcinoma: survival and recurrence in an unselected national cohort.

https://arctichealth.org/en/permalink/ahliterature125945
Source
Int J Radiat Oncol Biol Phys. 2012 Jun 1;83(2):e173-80
Publication Type
Article
Date
Jun-1-2012
Author
Anne Gry Bentzen
Marianne G Guren
Eva H Wanderås
Gunilla Frykholm
Kjell M Tveit
Tom Wilsgaard
Olav Dahl
Lise Balteskard
Author Affiliation
Department of Oncology, University Hospital of Northern Norway, Tromsø, Norway. anne.gry.bentzen@unn.no
Source
Int J Radiat Oncol Biol Phys. 2012 Jun 1;83(2):e173-80
Date
Jun-1-2012
Language
English
Publication Type
Article
Keywords
Adult
Age Factors
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Anus Neoplasms - mortality - pathology - therapy
Carcinoma, Squamous Cell - mortality - pathology - therapy
Chemoradiotherapy - methods
Cisplatin - administration & dosage
Cohort Studies
Colostomy - utilization
Disease-Free Survival
Drug Administration Schedule
Female
Fluorouracil - administration & dosage
Groin
Guideline Adherence
Humans
Lymphatic Irradiation - methods
Male
Middle Aged
Mitomycin - administration & dosage
Neoplasm Recurrence, Local - mortality
Neoplasm, Residual
Norway - epidemiology
Radiotherapy Dosage
Remission Induction
Salvage Therapy - methods
Sex Factors
Survival Rate
Treatment Outcome
Abstract
To evaluate treatment results, elucidate whether national guidelines were followed, and identify areas demanding further treatment optimization.
Between July 2000 and June 2007, 328 patients were treated with curatively intended chemoradiotherapy (CRT) for nonmetastatic squamous cell carcinoma of the anal region, according to national treatment guidelines based on tumor stage.
Complete response after CRT was obtained in 87% of patients, rising to 93% after salvage surgery. Chemotherapy, elective irradiation of the groin and salvage surgery were performed to a lesser extent in elderly patients, mainly because of frailty and comorbidity. Recurrence occurred in 24% of the patients, resulting in a 3- and 5-year recurrence-free survival (RFS) of 79% and 74%, respectively. Locoregional recurrences dominated, most commonly in the primary tumor site. Recurrence was treated with curative intent in 45% of the cases. The 3- and 5-year overall survival were 79% and 66%, and cancer-specific survival (CSS) were 84% and 75%, respectively. The risk of adverse outcome increased significantly with more locally advanced tumors and for male gender in multivariable analyses for RFS and CSS.
The treatment results are in accordance with similar cohorts. The primary treatment control rate was high, but there was a significant risk of locoregional recurrence in advanced tumors. The loyalty to national guidelines was broad, although individual adjustments occurred. However, caution to avoid toxicity must not lead to inadequate treatment. Male gender seems to have inferior outcome.
PubMed ID
22436791 View in PubMed
Less detail

Chemotherapy in gastric cancer: an economic evaluation of the FAM (5-fluorouracil, adriamycin, mitomycin C) versus ELF (etoposide, leucovorin, 5-fluorouracil) regimens.

https://arctichealth.org/en/permalink/ahliterature214171
Source
J Chemother. 1995 Oct;7(5):455-9
Publication Type
Article
Date
Oct-1995
Author
J. Norum
V. Angelsen
Author Affiliation
Department of Oncology, University Hospital of Tromsø, Norway.
Source
J Chemother. 1995 Oct;7(5):455-9
Date
Oct-1995
Language
English
Publication Type
Article
Keywords
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols - economics - therapeutic use
Cost-Benefit Analysis
Doxorubicin - administration & dosage - economics
Etoposide - administration & dosage - economics
Female
Fluorouracil - administration & dosage - economics
Humans
Leucovorin - administration & dosage - economics
Levoleucovorin
Male
Middle Aged
Mitomycin - administration & dosage - economics
Stomach Neoplasms - drug therapy - economics
Abstract
The prognosis in gastric cancer has been almost unchanged for the last 20 years. At the time of diagnosis the majority of patients have disseminated disease. The 5-year survival is only about 15%. Several efforts with numerous antineoplastic regimens have been studied. The most widely used regimen has been the FAM (5-fluorouracil, adriamycin, mitomycin C) regimen. Because of the cardiotoxicity and dose intensity of the FAM regimen, a low toxicity regimen, the ELF (etoposide, leucovorin, 5-fluorouracil) regimen, has been introduced. We present the data from the treatment of 26 patients (17 FAM, 9 ELF) with advanced gastric cancer at the University Hospital of Tromsø. The monthly costs of FAM and ELF treatment were calculated to a price of 553 pounds and 2976 pounds (British pounds). The median survival of 5 months (FAM) and 6 months (ELF) is in accordance with other studies. Assuming that the median survival in our study is correct, the cost of one year saved was 123,834 pounds, while the cost of one QALY (quality adjusted life year) employing the ELF compared to the FAM regimen was 104,334 pounds. We conclude that the standard ELF regimen too expensive in the treatment of gastric cancer.
PubMed ID
8596132 View in PubMed
Less detail

Complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastasis in Norway: Prognostic factors and oncologic outcome in a national patient cohort.

https://arctichealth.org/en/permalink/ahliterature280446
Source
J Surg Oncol. 2016 Aug;114(2):222-7
Publication Type
Article
Date
Aug-2016
Author
Ida S Frøysnes
Stein G Larsen
Milan Spasojevic
Svein Dueland
Kjersti Flatmark
Source
J Surg Oncol. 2016 Aug;114(2):222-7
Date
Aug-2016
Language
English
Publication Type
Article
Keywords
Adult
Aged
Antibiotics, Antineoplastic - administration & dosage
Colorectal Neoplasms - pathology
Combined Modality Therapy
Cytoreduction Surgical Procedures
Female
Humans
Hyperthermia, Induced
Male
Middle Aged
Mitomycin - administration & dosage
Norway
Peritoneal Neoplasms - secondary - therapy
Postoperative Complications
Prognosis
ROC Curve
Survival Analysis
Treatment Outcome
Young Adult
Abstract
Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) can offer long-term survival to patients with resectable peritoneal metastasis (PM) from colorectal cancer (CRC), a condition with otherwise dismal prognosis. This study describes short- and long-term outcome in a national patient cohort and aims to identify prognostic factors.
All patients treated with CRS-HIPEC for non-appendiceal PM-CRC in Norway 2004-2013 were included (n?=?119), and outcome and potential prognostic factors were examined using survival- and ROC-curve analysis.
Five-year overall survival (OS) and disease-free survival (DFS) were 36% and 14%, respectively, with 45 months median follow-up. The only factor associated with OS in multivariable analysis was peritoneal cancer index (PCI), with HR 1.05 (1.01-1.09) for every increase in PCI-score (P?=?0.015). Peritoneal relapse was associated with shorter OS than distant metastasis (P?=?0.002). ROC-curves identified PCI?>?12 as a marker with 100% specificity for prediction of disease relapse. Severe postoperative complications (Clavien-Dindo?=?3) occurred in 15% of patients and there was no 100-day mortality.
Long-term outcome was in line with published results, morbidity was acceptable and there was no 100-day mortality. The results reemphasize CRS-HIPEC as an important treatment option in PM-CRC, with particularly good results in patients with PCI?
PubMed ID
27173150 View in PubMed
Less detail

Endophthalmitis and severe blebitis following trabeculectomy. Epidemiology and risk factors; a single-centre retrospective study.

https://arctichealth.org/en/permalink/ahliterature260702
Source
Acta Ophthalmol. 2014 Aug;92(5):426-31
Publication Type
Article
Date
Aug-2014
Author
Örjan Wallin
Abdullah M Al-ahramy
Mats Lundström
Per Montan
Source
Acta Ophthalmol. 2014 Aug;92(5):426-31
Date
Aug-2014
Language
English
Publication Type
Article
Keywords
Aged
Aged, 80 and over
Alkylating Agents - administration & dosage
Case-Control Studies
Cataract Extraction - statistics & numerical data
Conjunctiva - physiology
Conjunctivitis - epidemiology - microbiology
Endophthalmitis - epidemiology - microbiology
Eye Infections, Bacterial - epidemiology - microbiology
Female
Fistula
Humans
Incidence
Male
Middle Aged
Mitomycin - administration & dosage
Postoperative Complications
Retrospective Studies
Risk factors
Sweden - epidemiology
Trabeculectomy - statistics & numerical data
Abstract
To study the epidemiology and risk factors of early- and late-onset postoperative endophthalmitis (PE) and severe blebitis following trabeculectomy.
Retrospective, single-centre, observational study with a case-control design in part. Patients sustaining PE and severe blebitis following trabeculectomy or a combined trabeculectomy with a cataract extraction procedure performed from 1990 through 2008 and diagnosed from 1990 through 2012 were recorded at St Erik Eye Hospital. Incidence data were calculated with help from the hospital records. Notes data of cases and of six randomly selected but procedure matched control patients for each case were compared.
The joint rate of infection was 0.46% or 34 incidents in 7402 procedures. The frequency of early (occurring
PubMed ID
24020653 View in PubMed
Less detail

[Enhancement of anti-tumor effects by arterial embolization combined with hyperthermia in the treatment of hepatic tumors]

https://arctichealth.org/en/permalink/ahliterature26172
Source
Gan To Kagaku Ryoho. 1987 Feb;14(2):396-403
Publication Type
Article
Date
Feb-1987
Author
Y. Tanaka
T. Murata
M. Yoshida
S. Kawa
S. Sawada
Source
Gan To Kagaku Ryoho. 1987 Feb;14(2):396-403
Date
Feb-1987
Language
Japanese
Publication Type
Article
Keywords
Animals
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Cisplatin - administration & dosage
Doxorubicin - administration & dosage
Embolization, Therapeutic
English Abstract
Humans
Hyperthermia, Induced
Injections, Intra-Arterial
Liver Circulation
Liver Neoplasms - pathology - therapy
Male
Microspheres
Middle Aged
Mitomycin
Mitomycins - administration & dosage
Rabbits
Starch - administration & dosage
Abstract
The effectiveness of arterial embolization using DSM (Degradable Starch Microspheres, Spherex, Sweden) combined with hyperthermia were investigated in the treatment of VX2 carcinoma in rabbits and also in human hepatic tumors. These microspheres temporarily obstructed the blood flow at the precapillary level. The blood flow in the tumor was inhibited to a greater extent and for a longer period than in normal muscle. The rise in temperature at the tumor site during heating was shown to be significantly higher than in muscle. The pH in the tumor clearly showed a stronger degree of inhibition than that achieved with hyperthermia alone. Histological examination demonstrated no marked damage to the muscle following DSM + hyperthermia. In the patients with hepatic tumor, hyperthermia was performed using an RF Thermotron 8 (8 MHz) externally, followed by injection of 15 ml of DSM combined with anti-cancer drugs via a catheter. The rise of temperature in DSM + chemo-hyperthermia during heating showed a higher value than that with hyperthermia alone and effective cases (PR) totalled 5 from among 8 cases treated. It was concluded that the heating efficiency may be improved by arterial chemo-embolization in the treatment of hepatic tumors.
PubMed ID
3101604 View in PubMed
Less detail

[Hepatic arterial infusion chemotherapy and hyperthermia with degradable starch microspheres in primary and metastatic liver malignancies]

https://arctichealth.org/en/permalink/ahliterature4162
Source
Gan To Kagaku Ryoho. 1989 Aug;16(8 Pt 2):2822-6
Publication Type
Article
Date
Aug-1989
Author
T. Miura
K. Haida
Author Affiliation
Hanzomon Hospital, Dept. of Surgery.
Source
Gan To Kagaku Ryoho. 1989 Aug;16(8 Pt 2):2822-6
Date
Aug-1989
Language
Japanese
Publication Type
Article
Keywords
Antineoplastic Combined Chemotherapy Protocols - administration & dosage - therapeutic use
Carcinoma, Hepatocellular - blood - therapy
Combined Modality Therapy
Embolization, Therapeutic - methods
English Abstract
Fluorouracil - administration & dosage
Hepatic Artery
Humans
Hyperthermia, Induced
Infusions, Intra-Arterial
Liver Neoplasms - blood - secondary - therapy
Microspheres
Mitomycin
Mitomycins - administration & dosage
Pilot Projects
Starch - administration & dosage
Tumor Markers, Biological - blood
Abstract
In non-resectable liver malignancies, concurrent administration of degradable starch microspheres (DSM) and anticancer drugs via hepatic artery has been suggested as a method to increase the concentration of drugs in tumor tissue. DSM also has been known to increase the temperature of tissue when administered at the time of hyperthermia. In the light of these findings we have studied the effect of hepatic arterial infusion of 5-FU and mitomycin C and local hyperthermia in combination with hepatic arterial flow arrest with DSM for the treatment of hepatoma in 11 patients and metastatic liver cancer in 38 patients. Of the 8 patients having hepatoma with increased AFP, all the patients showed a decrease of AFP following the therapy with an average ratio of 65% decrease. Of the 33 patients with hepatic metastasis with increased CEA, 32 patients (96%) showed a decrease of CEA following the therapy (control group with infusion chemotherapy and hyperthermia without DSM: 58%) with an average decrease ratio of 59% (control group: 43%). Of the 26 patients with increased CA 19-9, 22 patients (84%) showed a decrease of CA 19-9 (control group: 75%) with an average decrease ratio of 52% (control group: 29%). This pilot study suggests that the concurrent hepatic arterial infusion of 5-FU, mitomycin C and DSM with local hyperthermia may have the potential to improve selective regional drug effect.
PubMed ID
2551225 View in PubMed
Less detail

[Hepatic arterial infusion chemotherapy and hyperthermia with degradable starch microspheres in primary and metastatic liver malignancies]

https://arctichealth.org/en/permalink/ahliterature4170
Source
Gan To Kagaku Ryoho. 1988 Aug;15(8 Pt 2):2578-82
Publication Type
Article
Date
Aug-1988
Author
T. Miura
K. Haida
Author Affiliation
Hanzomon Hospital, Department of Surgery, Tokyo, Japan.
Source
Gan To Kagaku Ryoho. 1988 Aug;15(8 Pt 2):2578-82
Date
Aug-1988
Language
Japanese
Publication Type
Article
Keywords
Antineoplastic Combined Chemotherapy Protocols - administration & dosage - therapeutic use
Carcinoma, Hepatocellular - drug therapy - therapy
Combined Modality Therapy
Embolization, Therapeutic - methods
English Abstract
Fluorouracil - administration & dosage
Hepatic Artery
Humans
Hyperthermia, Induced
Infusions, Intra-Arterial
Liver Neoplasms - drug therapy - secondary - therapy
Microspheres
Mitomycin
Mitomycins - administration & dosage
Pilot Projects
Starch - administration & dosage
Tumor Markers, Biological - blood
Abstract
In non-resectable liver malignancies, concurrent administration of degradable starch microspheres (DSM) and anticancer drugs via hepatic artery has been suggested as a method to increase the concentration of drugs in tumor tissue. DSM also has been known to increase the temperature of tissue when administered at the time of hyperthermia. In the light of these findings, we have studied the effect of hepatic arterial infusion of 5-FU and mitomycin C and 2450 MHz microwave local hyperthermia in combination with hepatic arterial flow arrest with DSM for the treatment of hepatoma in 10 patients and metastatic liver cancer in 20 patients. Of the 8 patients with hepatoma with increased AFP, all the patients showed a decrease of AFP following therapy with an average decrease ratio of 64%. Of the 17 patients with hepatic metastasis with increased CEA, 16 patients (94%) showed a decrease of CEA following the therapy (control group with infusion chemotherapy and hyperthermia without DSM: 66%) with average decrease ratio of 50% (control group: 27%). Of the 15 patients with increased CA 19-9, 13 patients (86%) showed a decrease of CA 19-9 (control group: 62%) with an average decrease ratio of 52% (control group: 21%). This pilot study suggests that the concurrent hepatic arterial infusion of 5-FU, mitomycin C and DSM with local hyperthermia may have the potential to improve selective regional drug effect.
PubMed ID
2843126 View in PubMed
Less detail

Intra-arterial chemotherapy with mitomycin C in gallbladder cancer: a follow-up study.

https://arctichealth.org/en/permalink/ahliterature16877
Source
J Surg Oncol. 2005 Aug 1;91(2):102-6
Publication Type
Article
Date
Aug-1-2005
Author
Michaela K Bode
Jukka Perälä
Jyrki T Mäkelä
Sami Leinonen
Author Affiliation
Department of Radiology, Oulu University Hospital, Oulu, Finland. Michaela.Bode@mail.suomi.net
Source
J Surg Oncol. 2005 Aug 1;91(2):102-6
Date
Aug-1-2005
Language
English
Publication Type
Article
Keywords
Adenocarcinoma - drug therapy - mortality - pathology - surgery
Adult
Antibiotics, Antineoplastic - administration & dosage - adverse effects
Combined Modality Therapy
Drug Administration Schedule
Follow-Up Studies
Gallbladder Neoplasms - drug therapy - mortality - pathology - surgery
Humans
Infusions, Intra-Arterial
Middle Aged
Mitomycin - administration & dosage - adverse effects
Neoplasm Staging
Survival Rate
Treatment Outcome
Abstract
BACKGROUND AND OBJECTIVES: There is only limited and somewhat controversial information available on hepatic artery infusion of cytotoxic agents in gallbladder cancer. We report the results of 5-year follow-up of all gallbladder cancer patients treated with surgery and intra-arterial mitomycin C or mitomycin C alone in our hospital during 15 years. METHODS: Thirty-five patients with gallbladder cancer were treated with superselective intra-arterial chemotherapy (SIAC) with mitomycin C during 1981-1996. Survival was measured from diagnosis, and all patients were followed up until death or the end of January 2002. Cumulative survival rates and median survival times were calculated for all patients, according to response to treatment and staging. The data are presented as 5-year survival. RESULTS: Median survival times after SIAC for all patients, responders, and non-responders were 48, 60+, and 8.5 months, respectively. Overall response rate was 60%. Survival was significantly better for tumors limited to the gallbladder wall, as expected. Drug toxicity occurred in half of the patients, requiring cessation of chemotherapy in 25% of the cases. CONCLUSIONS: The median survival of gallbladder cancer patients treated with surgery and SIAC seems to be significantly better compared to the previously reported outcome of surgical treatment alone. Drug toxicity limits the use of i.a. chemotherapy and requires careful monitoring for early side-effects.
PubMed ID
16028283 View in PubMed
Less detail

[Intra-arterial infusion chemotherapy for metastatic liver cancer (author's transl)]

https://arctichealth.org/en/permalink/ahliterature4264
Source
Rinsho Hoshasen. 1979;24(10):1075-82
Publication Type
Article
Date
1979

22 records – page 1 of 3.